NCAPG2 and central nervous system cancer: The results consistently showed that glioma patients with a higher NCAPG2 expression had a significantly deteriorative OS compared to those with a low NCAPG2 level, including the subgroup of WHO grade 3, 1p/19q non-codeletion, astrocytoma, Oligodendroglioma, subgroup of PD, Male, Female, age >40, age <40, Race, white, Lateralty, right and left (Figures 5A–C).